Mirabella Financial Services LLP Has $2.41 Million Holdings in AbbVie Inc. $ABBV

Mirabella Financial Services LLP trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 69.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,919 shares of the company’s stock after selling 29,471 shares during the period. Mirabella Financial Services LLP’s holdings in AbbVie were worth $2,409,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Conning Inc. increased its holdings in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Dohj LLC raised its position in AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after buying an additional 1,335 shares during the last quarter. First Hawaiian Bank lifted its stake in AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after acquiring an additional 60 shares in the last quarter. BankPlus Trust Department boosted its holdings in AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after acquiring an additional 855 shares during the last quarter. Finally, Whittier Trust Co. grew its stake in shares of AbbVie by 4.0% in the 2nd quarter. Whittier Trust Co. now owns 237,030 shares of the company’s stock worth $43,997,000 after acquiring an additional 9,073 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 0.7%

Shares of ABBV opened at $228.68 on Friday. The firm has a market cap of $404.17 billion, a P/E ratio of 173.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The business has a 50-day moving average of $228.19 and a 200 day moving average of $207.90.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wells Fargo & Company boosted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Citigroup dropped their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Evercore ISI raised their target price on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Finally, HSBC set a $225.00 price target on shares of AbbVie in a report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.